BioPharmSignal logoBioPharmSignal

Biotech News

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Neuronetics (STIM)NeuroneticsEarnings

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help,

Open original release

Related news

STIMNeuronetics2026-04-21 12:30 EST

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

STIMNeuronetics2026-03-17 11:50 EST

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

ICCMIceCure Medical2026-05-06 12:30 EST

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

ICCMIceCure Medical2026-05-12 12:30 EST

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

AORTArtivion2026-05-07 20:05 EST

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

PLSEPulse Biosciences2026-05-04 11:00 EST

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

AORTArtivion2026-04-23 20:15 EST

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results

View all latest news

Neuronetics

Neuronetics is a medical device company focused on neurostimulation for depression and mental-health treatment. Its business is centered on procedure-based adoption of non-drug therapy.

Recent company news

STIMNeuronetics2026-06-02 20:30 EST

Neuronetics Appoints Robert Greene as Senior Vice President Sales

STIMNeuronetics2026-06-02 12:32 EST

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

STIMNeuronetics2026-05-14 12:32 EST

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

STIMNeuronetics2026-05-05 11:50 EST

Neuronetics Reports First Quarter 2026 Financial and Operating Results

STIMNeuronetics2026-04-29 20:30 EST

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
1.81 USD
Market cap
108.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States